Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Qyuns Therapeutics Co., Ltd. Class H ( (HK:2509) ) has shared an update.
Qyuns Therapeutics Co., Ltd. has entered into a global exclusive license agreement with Roche, granting Roche the rights to develop, manufacture, and commercialize QX031N. This agreement includes an upfront payment of $75 million to Qyuns and potential milestone payments up to $995 million, along with tiered royalties on future sales. The collaboration is expected to enhance Qyuns’ industry positioning by advancing QX031N as a potential ‘First-in-class’ and ‘Best-in-disease’ therapy for respiratory diseases, potentially impacting stakeholders positively with significant financial and market opportunities.
The most recent analyst rating on (HK:2509) stock is a Hold with a HK$24.50 price target. To see the full list of analyst forecasts on Qyuns Therapeutics Co., Ltd. Class H stock, see the HK:2509 Stock Forecast page.
More about Qyuns Therapeutics Co., Ltd. Class H
Qyuns Therapeutics Co., Ltd. is a biopharmaceutical company based in China, focusing on developing innovative therapies for respiratory diseases. Their primary product, QX031N, is a long-acting bispecific antibody targeting TSLP and IL-33, proteins involved in inflammatory processes related to respiratory conditions such as COPD and asthma.
Average Trading Volume: 926,375
Technical Sentiment Signal: Buy
Current Market Cap: HK$5.4B
See more data about 2509 stock on TipRanks’ Stock Analysis page.